Lanadelumab-flyo

From WikiMD.org
Jump to navigation Jump to search

Lanadelumab-flyo (pronounced as lana del' ue mab) is a monoclonal antibody used for the prevention of attacks of hereditary angioedema (HAE) in patients aged 12 years and older. It is marketed under the brand name Takhzyro.

Etymology

The name "Lanadelumab-flyo" is derived from the International Nonproprietary Names (INN), where "Lana-" refers to the target (plasma kallikrein), "-lumab" is a suffix for monoclonal antibodies, and "-flyo" indicates the production method (recombinant DNA technology in Chinese hamster ovary cells).

Pharmacology

Lanadelumab-flyo is a fully human monoclonal antibody that binds to plasma kallikrein and inhibits its binding to high molecular weight kininogen (HMWK), thereby preventing the production of bradykinin, a peptide that causes blood vessels to dilate and become permeable, leading to the symptoms of HAE.

Usage

Lanadelumab-flyo is used for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. It is administered by subcutaneous injection every 2 weeks.

Side Effects

Common side effects of Lanadelumab-flyo include injection site reactions, upper respiratory tract infection, headache, rash, muscle pain, dizziness, and diarrhea.

Related Terms

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski